Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein

Clinical and Translational Immunology

Volumn 4, Issue 1, 2015, Pages

  Cross, Ryan S ^a   Malaterre, Jordane ^a   Davenport, Alexander J ^a   Carpinteri, Sandra ^a   Anderson, Robin L ^a   Darcy, Phillip K ^a   Ramsay, Robert G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DNA VACCINE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN MYB; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURFACE; COLORECTAL CANCER; CONTROLLED STUDY; CT26 CELL LINE; DNA IMMUNIZATION; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LOW DRUG DOSE; MC-38 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR VOLUME;

EID: 84944875663     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2014.29     Document Type: Article

References (36)

1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960–1964.
2. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007; 67: 1883–1886.
3. Felsher DW. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit? Cancer Res 2008; 68: 3081–3086 discussion 3086.
4. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction—a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006; 3: 448–457.
5. Ramsay RG, Ciznadija D, Mantamadiotis T, Anderson R, Pearson R. Expression of stress response protein glucose regulated protein-78 mediated by c-Myb. Int J Biochem Cell Biol 2005; 37: 1254–1268.
6. Corrigall VM, Vittecoq O, Panayi GS. Binding immunoglobulin protein-treated peripheral blood monocyte-derived dendritic cells are refractory to maturation and induce regulatory T-cell development. Immunology 2009; 128: 218–226.
7. Biroccio A, Benassi B, D'Agnano I, D'Angelo C, Buglioni S, Mottolese M et al. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol 2001; 158: 1289–1299.
8. Ramsay RG, Thompson MA, Hayman JA, Reid G, Gonda TJ, Whitehead RH. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa. Cell Growth Differ 1992; 3: 723–730.
9. Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev 2011; 25: 1628–1640.
10. Miao RY, Drabsch Y, Cross RS, Cheasley D, Carpinteri S, Pereira L et al. MYB is essential for mammary tumorigenesis. Cancer Res 2011; 71: 7029–7037.
11. Carpinteri S, Williams BB, Miao Yu R, Cullinane C, Malaterre J, Norris MD et al. Optimizing DNA vaccines against nuclear oncogenes. Immunogastroenterology 2012; 1: 108–118.
12. Renard V, Sonderbye L, Ebbehoj K, Rasmussen PB, Gregorius K, Gottschalk T et al. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J Immunol 2003; 171: 1588–1595.
13. Fryauff DJ, Mouzin E, Church LW, Ratiwayanto S, Hadiputranto H, Sutamihardja MA et al. Lymphocyte response to tetanus toxin T-cell epitopes: effects of tetanus vaccination and concurrent malaria prophylaxis. Vaccine 1999; 17: 59–63.
14. Williams BB, Wall M, Miao RY, Williams B, Bertoncello I, Kershaw MH et al. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer. Cancer Immunol Immunother 2008; 57: 1635–1645.
15. Kanei-Ishii C, Yasukawa T, Morimoto RI, Ishii S. c-Myb-induced trans-activation mediated by heat shock elements without sequence-specific DNA binding of c-Myb. J Biol Chem 1994; 269: 15768–15775.
16. Cheasley D, Pereira L, Lightowler S, Vincan E, Malaterre J, Ramsay RG. Myb controls intestinal stem cell genes and self-renewal. Stem Cells 2011; 29: 2042–2050.
17. Ciznadija D, Tothill R, Waterman ML, Zhao L, Huynh D, Yu RM et al. Intestinal adenoma formation and MYC activation are regulated by cooperation between MYB and Wnt signaling. Cell Death Differ 2009; 16: 1530–1538.
18. Nicolaides NC, Gualdi R, Casadevall C, Manzella L, Calabretta B. Positive autoregulation of c-myb expression via Myb binding sites in the 5' flanking region of the human c-myb gene. Mol Cell Biol 1991; 11: 6166–6176.
19. von Boehmer H, Daniel C. Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov 2013; 12: 51–63.
20. + T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186–192.
21. + regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490–500.
22. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res 2012; 72: 3439–3444.
23. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011; 33: 369–383.
24. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24: 207–212.
25. Smith KA, Tam VL, Wong RM, Pagarigan RR, Meisenburg BL, Joea DK et al. Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine 2009; 27: 2603–2615.
26. + T-cell responses by soluble PD-1. J Immunother 2011; 34: 297–306.
27. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer 2008; 8: 523–534.
28. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134–144.
29. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454.
30. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122–133.
31. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537–1544.
32. + early effector T cells identified at tumor site in primary and metastatic melanoma. Cancer Res 2010; 70: 8378–8387.
33. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167–3175.
34. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013; 19: 462–468.
35. Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv Surg 2011; 45: 341–360.
36. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975; 35: 2434–2439.